Actinium Highlights Data From Completed Phase 1b Combination Trial Of Actimab-A + CLAG-M In r/r AML At 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Actinium Pharmaceuticals presented data from its completed Phase 1b trial of Actimab-A combined with CLAG-M for relapsed or refractory acute myeloid leukemia (r/r AML) at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting.
June 11, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Actinium Pharmaceuticals presented promising data from its Phase 1b trial of Actimab-A combined with CLAG-M for r/r AML, which could positively impact the stock price.
The presentation of positive data from a clinical trial can lead to increased investor confidence and a potential rise in stock price. The data was presented at a significant annual meeting, adding credibility.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100